Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hi-Tech Pharmaceuticals Indicted For Online “Generic” Drug Enterprise

This article was originally published in The Tan Sheet

Executive Summary

A federal grand jury has indicted Hi-Tech Pharmaceuticals and 11 individuals on multiple felony charges for allegedly selling adulterated and unapproved new drugs via the Internet, the Drug Enforcement Agency announced Sept. 20

You may also be interested in...



Hi-Tech Hunts Growth As FTC Picks Up Scent On Disputed Weight Loss Claims

FTC asks a federal court to re-instate a contempt order stemming from Hi-Tech Pharmaceuticals’ misleading claims for weight loss supplements that an appellate court overturned. Hi-Tech, meanwhile, argues for recusal of the judge who found the firm in contempt and ordered two executives to jail.

Hi-Tech Hunts Growth As FTC Picks Up Scent On Disputed Weight Loss Claims

FTC asks a federal court to re-instate a contempt order stemming from Hi-Tech Pharmaceuticals’ misleading claims for weight loss supplements that an appellate court overturned. Hi-Tech, meanwhile, argues for recusal of the judge who found the firm in contempt and ordered two executives to jail.

Hi-Tech CEO Could Face Jail For Violating Court Order To Recall Weight Loss Products

A federal judge soon will decide whether Hi-Tech Pharmaceuticals CEO Jared Wheat goes to jail for failing to recall weight loss products marketed with false claims. Wheat has a history of run-ins with FDA, FTC and DEA for marketing supplements adulterated with drugs and making false claims for products.

Related Content

Topics

UsernamePublicRestriction

Register

PS099783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel